PDB46 COST-UTILITY OF INSULIN DETEMIR VERSUS NPH FOR TYPE I DIABETES PATIENTS TREATED WITH BASAL-BOLUS THERAPY IN A FRENCH SETTING, A MODELING EVALUATION BASED ON RESULTS FROM A META-ANALYSIS OF THREE CLINICAL TRIALS